单片药片组合疗法是高血压治疗的标准,但现在是下一步的时间:实施
Jose P Lopez-Lopez1, Patricio Lopez-Jaramillo2
1Masira Research Institute, Universidad de Santander (UDES), Bucaramanga, Colombia; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
Med (New York, N.Y.)
|December 14, 2024
概括
一种低剂量单片药物组合有效降低了成人高血压 (BP). 与双重疗法相比,这种新的治疗选择显示出明显的血压降低,但不增加不良事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 高血压是全球主要的健康问题,需要有效的治疗策略.
- 目前的指导方针建议用于控制不良的血压 (BP) 的联合治疗.
研究的目的:
- 评估一种用于高血压管理的新型低剂量三药组合药物的疗效和安全性.
- 为了比较单片药物三重组合与双片药物组合的疗效.
主要方法:
- GMRx2试验涉及患有高血压的成年人.
- 参与者接受了单片三重组合药物 (特尔米沙坦,阿姆洛迪平,英达帕米德) 或双重组合药物.
- 在12周的时间内评估血压水平.
主要成果:
- 三重组合在12周后显著降低了血压水平,与所有双重组合相比.
- 在三重组和双重组组之间没有观察到不良事件的显著差异.
- 这证明了三重疗法的卓越疗效.
结论:
- 低剂量单片药的telmisartan,amlodipine和indapamide组合是一种安全有效的选择,用于管理高血压.
- 与双重疗法相比,这种新的治疗策略提供了更好的血压控制.
- 这些发现支持使用这种组合来加强高血压管理.
相关概念视频
01:28Drug Therapy
38
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
38
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
140
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
140
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
473
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
473
01:25Antihypertensive Drugs: Direct Renin Inhibitors
487
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
487
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147